دورية أكاديمية
A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein.
| العنوان: | A stable platform for the production of virus-like particles pseudotyped with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein. |
|---|---|
| المؤلفون: | Roy S; CHU de Québec-Université Laval Research Center (Oncology division), Université Laval Cancer Research Center, Québec, Qc, Canada., Ghani K; CHU de Québec-Université Laval Research Center (Oncology division), Université Laval Cancer Research Center, Québec, Qc, Canada; BioVec Pharma, Québec, Qc, Canada., de Campos-Lima PO; Boldrini Children's Center, Campinas, Brazil; Functional and Molecular Biology Graduate Program, State University of Campinas, Brazil., Caruso M; CHU de Québec-Université Laval Research Center (Oncology division), Université Laval Cancer Research Center, Québec, Qc, Canada; BioVec Pharma, Québec, Qc, Canada; Department of Molecular Biology, Medical Biochemistry and Pathology, Faculty of Medicine, Université Laval, Québec, Qc, Canada. Electronic address: manuel.caruso@crchudequebec.ulaval.ca. |
| المصدر: | Virus research [Virus Res] 2021 Apr 02; Vol. 295, pp. 198305. Date of Electronic Publication: 2021 Jan 19. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8410979 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7492 (Electronic) Linking ISSN: 01681702 NLM ISO Abbreviation: Virus Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Amsterdam : Elsevier Science, c1984- |
| مواضيع طبية MeSH: | COVID-19 Vaccines/*immunology , Spike Glycoprotein, Coronavirus/*biosynthesis , Virion/*genetics, Cell Line ; Humans ; Moloney murine leukemia virus/genetics ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/immunology ; Vaccines, Synthetic/immunology ; Virion/immunology |
| مستخلص: | In this study, we showed that a codon optimized version of the spike (S) protein of SARS-CoV-2 can migrate to the cell membrane. However, efficient production of Moloney murine leukemia (MLV) infectious viral particles was only achieved with stable expression of a shorter S version in C-terminal (ΔS) in MLV Gag-pol expressing cells. As compared to transient transfections, this platform generated viruses with a 1000-fold higher titer. ΔS was 15-times more efficiently incorporated into VLPs as compared to S, and that was not due to steric interference between the cytoplasmic tail and the MLV capsid, as similar differences were also observed with extracellular vesicles. The amount of ΔS incorporated into VLPs released from producer cells was high and estimated at 1.25 μg/mL S2 equivalent (S is comprised of S1 and S2). The resulting VLPs could potentially be used alone or as a boost of other immunization strategies for COVID-19. (Copyright © 2021 Elsevier B.V. All rights reserved.) |
| فهرسة مساهمة: | Keywords: COVID-19; Coronavirus; Moloney; Retrovirus; SARS-CoV-2; VLP; Vaccine; Virus-like particle |
| المشرفين على المادة: | 0 (COVID-19 Vaccines) 0 (Spike Glycoprotein, Coronavirus) 0 (Vaccines, Synthetic) 0 (spike protein, SARS-CoV-2) |
| تواريخ الأحداث: | Date Created: 20210122 Date Completed: 20210323 Latest Revision: 20210323 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC7817443 |
| DOI: | 10.1016/j.virusres.2021.198305 |
| PMID: | 33482242 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1872-7492 |
|---|---|
| DOI: | 10.1016/j.virusres.2021.198305 |